David S Hong

71PUBLICATIONS
565CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (71)

|Sep 04, 2026
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers.

|Aug 26, 2026
Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.

|Aug 11, 2026
Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

|Jul 30, 2026
"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal?

|Jun 04, 2026
Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications.

|May 06, 2026
NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types.

Pageof 12

Frequent Collaborators

14 joint publications

Vivek Subbiah

13 joint publications

Aung Naing

11 joint publications

Janku Filip

11 joint publications

Funda Meric-Bernstam